Specialist manufacturer of gastrointestinal products,
Given Imaging Ltd.
) confirmed the success of its PillCam ESO to support triage
patients with upper gastrointestinal bleeding (UGIB). It also
revealed details pertaining to Bravo Systems, indicating that it
can increase patient pH monitoring up to four days for those who
suffer from gastroesophageal reflux disease (GERD). The
announcements are supported by clinical trials and data from
reputed universities across the globe.
According to Given Imaging's Chief Medical Officer, the new
studies reassert the efficiency of Bravo pH monitoring and PillCam
ESO in diagnosing, monitoring and triaging different kinds of
esophageal ailments. The prolonged monitoring of Bravo Systems will
provide meaningful feedback about patients' condition and their
daily lives. This will enable doctors to adjust the diet and drug
regimens of their patients accordingly. On the other hand,
PillCam ESO can detect malignant lesions in the upper
gastrointestinal tract. These lesions can result in fatal blood
loss if they remain undetected. PillCam ESO holds an advantage over
gastroscopy as it can identify lesions undetected by
Given Imaging enjoys worldwide market share of 85% and domestic
market share of 95%. Even though the company reported first quarter
revenue of $41.8 million (a 5% increase from the prior year
quarter), it has the scope to cater to a multi-billion dollar
market. The company also produces PillCam SB, a capsule endoscope
for the imaging of the small intestine. Its PillCam SB has the
highest potential as 85% of the domestic market remains
un-penetrated and the international market grows at 18%-20%.
However, with an aging population and increasing prevalence of
heartburn and other acid reflux symptoms, PillCam ESO is expected
to gain a strong foothold and leverage sales in the world
The company's Bravo Systems is a benchmark in the field of pH
monitoring. Bravo Systems earlier collected 48 hours of pH data for
heartburn symptoms. The increased 96-hour monitoring time will
allow clinicians to treat patients effectively.
The complementary product portfolio of Given Imaging is
accretive to top and bottom-line growth. With supportive statistics
and impending commercialization of the PillCam COLON, the company
is expected to meet its outlook of stable double-digit growth in
the current year. Its competitors providing medical imaging
GE Healthcare- a division of General Electric
) and the privately-owned
FUJIFILM Holdings Corporation
Given Imaging currently retains a Zacks #1 Rank, which
translates into a short-term 'Strong Buy' rating.
GENL ELECTRIC (GE): Free Stock Analysis Report
GIVEN IMAGING (GIVN): Free Stock Analysis
To read this article on Zacks.com click here.